Peripheral T-cell Lymphomas
5 clinical trials · Condition
◉ Watch Peripheral T-cell Lymphomas
| Record | Firm | Date |
|---|---|---|
| Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724) | National Cancer Institute (NCI) | 2019-04-18 |
| Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study (NCT02520219) | Nanjing NingQi Medicine Science and Technology Co., Ltd. | 2014-12-01 |
| Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas (NCT00704691) | University of Alabama at Birmingham | 2008-06-01 |
| Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas (NCT00453427) | Ontario Clinical Oncology Group (OCOG) | 2006-09-01 |
| Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas (NCT00374699) | Samsung Medical Center | 2006-04-01 |
Track Peripheral T-cell Lymphomas automatically
Every clearance here is in the API, with alerts when new ones post.